S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom

AbbVie (ABBV) ESG Score & Sustainability Data

$164.24
+1.70 (+1.05%)
(As of 04/17/2024 ET)

Key ESG Takeaways for AbbVie

The key takeaways are AI-generated and highlight the main contributors behind the net impact scores of AbbVie. The insights are based on millions of scientific articles, along with the company-specific product and service portfolio.
  • AbbVie seems to create the most significant positive value in categories , , and . The largest positive contribution comes from its impact, which is mostly driven by its Adalimumab, Ibrutinib, and Hepatitis medication products.
  • On the other hand, these positive outcomes are achieved by using resources or causing negative impacts in categories , , and . The negative contribution in the impact category seems to be driven mostly by its Ibrutinib, Adalimumab, and Venetoclax products.
  • To improve its net impact, a company can either grow its positive impacts, or reduce its negative impacts. For example, by doubling its Adalimumab business, AbbVie would improve its net impact ratio by 1 percentage points.

ABBV Impact Ratio

Net impact ratio represents the net impact of a company. It is defined as the (positive impacts - negative impacts) / positive impacts. The maximum value for net impact ratio is 100%, representing a theoretical company with no negative impacts. The minimum value is -∞. Net scores depend on the value sets that determine the importance of different impact categories.
+52.3%
The default value set, where each category is given the same weight.

Value Sets Value sets can be used to assess how different stakeholder values or emphasis on certain values might affect the net impact ratio.

Millennials
Value set of millennials (b. 1980 - 1999), based on Upright's annual Impact at Work survey.
+57.4%
Most Wanted Workforce
Value set of the most wanted workforce, based on Upright's annual Impact at Work survey.
+37.3%
Society First
Value set that emphasizes society impacts over other impacts.
-38.3%
Knowledge First
Value set that emphasizes knowledge impacts over other impacts.
+62.3%
Health First
Value set that emphasizes health impacts over other impacts.
+76.7%

AbbVie ESG Score + Net Impact Profile

ImpactNegativeScorePositive
+0.74
+0.74
+1.61
+1.61
+0.28
+0.28
-0.02
+0.07
+0.09
-0.22
-0.19
+0.03
+0.00
+0.00
+0.87
+0.87
-0.00
+0.00
+0.00
-1.79
-1.79
-1.11
+5.78
+6.89
-0.05
+0.68
+0.73
0.00
+0.00
-0.00
+0.00
+0.00
-0.01
+0.40
+0.41
-1.00
-0.97
+0.02
-0.24
-0.23
+0.01
-0.14
-0.14
+0.00
-0.10
-0.10
+0.00
-0.91
-0.90
+0.01

Upright Model Version 0.4.0
ESG Data Last Updated: March 29, 2022

About Upright's Net Impact Model

Upright's Net Impact Data quantifies the holistic value creation and impact of companies. It details both the negative and positive impacts a company has on the environment, health of people, society and knowledge, and forms a net sum of these costs and gains based on the economic costs of each impact category. The data is produced by Upright's Net Impact model, which is a mathematical model of the economy that produces continuously updated estimates of the net impact of companies by means of an information integration algorithm. The data is primarily sourced from the CORE open access database, which contains over 200 million scientific papers. Other sources of data include open databases published by the World Bank, IMF, WHO, OECD, IPCC, CDC and USDA.

AbbVie ESG Score - Frequently Asked Questions

How is AbbVie doing in terms of sustainability?

According to The Upright Project, which measures holistic value creation and impact of companies, AbbVie has a net impact ratio of 52.3%, indicating an overall positive sustainability impact. AbbVie seems to create the most significant positive value in the categories of Physical diseases, Taxes, and Creating knowledge. On the other hand, these positive outcomes are achieved by using resources or causing negative impacts in the categories of Scarce human capital, Physical diseases, and GHG emissions. Learn more on the sustainability of AbbVie.


More ESG Stocks and Research Tools

This page (NYSE:ABBV) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners